Expertise in
1
conditions

Dr. Matthew Kutny

Hematology | Oncology
Children's Of Alabama
1600 7th Ave S, 
Birmingham, AL 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
1
conditions
Children's Of Alabama
1600 7th Ave S, 
Birmingham, AL 

Overview

Matthew Kutny is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Kutny is highly rated in 1 condition, according to our data. His top areas of expertise are Leukemia, Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), Infantile Neutropenia, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 40 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in AL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
View 2 Less Insurance Carriers -

Locations

Children's of Alabama
1600 7th Ave S, Birmingham, AL 35233

Additional Areas of Focus

Dr. Kutny has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

39 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Selumetinib, Vinblastine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) With an Isocitrate Dehydrogenase-2 (IDH2) Mutation
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) With an Isocitrate Dehydrogenase-2 (IDH2) Mutation
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Procedure, Drug
Study Drugs: Enasidenib, Enasidenib Mesylate
Study Phase: Phase 2
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
View 8 Less Clinical Trials

31 Total Publications

PRMT1-mediated metabolic reprogramming promotes leukemogenesis.
PRMT1-mediated metabolic reprogramming promotes leukemogenesis.
Journal: eLife
Published: August 13, 2025
Similar Doctors
Andres Torres
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.3 miles away)
205-996-6074
Languages Spoken:
English
See accepted insurances

Andres Torres is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Torres is highly rated in 23 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Breast Cancer, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
5
conditions
Dr. Susan Bal
Hematology | Oncology
Expertise in
5
conditions
Dr. Susan Bal
Hematology | Oncology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.5 miles away)
205-801-9034
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Bal is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Bal is highly rated in 5 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
30
conditions
Dr. Amitkumar Mehta
Hematology
Expertise in
30
conditions
Dr. Amitkumar Mehta
Hematology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.5 miles away)
205-801-8415
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amitkumar Mehta is a Hematologist in Birmingham, Alabama. Dr. Mehta is highly rated in 30 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy.

Frequently Asked Questions about Dr. Matthew Kutny

How do I make an appointment with Dr. Matthew Kutny?

You can book an appointment with Dr. Matthew Kutny by calling their office at 205-638-9285. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew Kutny a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew Kutny is classified as an Advanced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew Kutny specialize in?

While Dr. Matthew Kutny is a Hematology, they have specific expertise in Leukemia, Febrile Neutropenia, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Matthew Kutny participate in research or clinical trials?

Yes. Dr. Matthew Kutny has published 31 articles and abstracts on conditions like Leukemia. You can view a list of Dr. Matthew Kutny's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew Kutny accept my insurance?

Dr. Matthew Kutny accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 205-638-9285 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kutny's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile